Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Brandes

Neurology Knoxville, TN Medical Doctor

NPI 1487761144 CMS profile 249217

2060 Lakeside Centre Way, Knoxville, TN 37922

Open in the dashboard

General payments

$412,138

581 records reported · program years 2019–2025

Research payments

$2,592

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,689 paid to institutions, not to them · program years 2019–2020

Through program year 2025, David Brandes of Knoxville, TN is reported in the CMS Open Payments database as having received $412,138 across 581 general payments and $2,592 in research payments paid to them. Separately, studies naming them as principal investigator received $5,689 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43 1
2024 General $172 3
2023 General $164 4
2022 General $43,598 73
2021 General $46,505 111
2020 General $97,738 117
2020 Research $443 2
2019 General $223,919 272
2019 Research $2,148 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Brandes
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to David Brandes were reported at $43. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year David Brandes Neurology median Middle half National median
2019 $223,919 $474 $118–$2,177 $163
2020 $97,738 $367 $82–$2,309 $114
2021 $46,505 $438 $104–$2,547 $132
2022 $43,598 $442 $103–$2,388 $149
2023 $164 $464 $119–$2,312 $160
2024 $172 $468 $119–$2,323 $164
2025 $43 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $170,118 146 payments
  2. Novartis Pharmaceuticals Corporation $48,505 88 payments
  3. Genzyme Corporation $47,666 58 payments
  4. Allergan Inc. $36,552 42 payments
  5. Genentech USA, Inc. $35,235 47 payments
  6. Celgene Corporation $23,825 37 payments
  7. Mallinckrodt Enterprises LLC $14,609 10 payments
  8. EMD Serono, Inc. $12,859 26 payments
  9. Mallinckrodt Hospital Products Inc. $8,003 6 payments
  10. Horizon Therapeutics plc $7,938 8 payments
  11. Other $6,828 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $304,172 107 payments
  2. Consulting Fee $51,607 11 payments
  3. Travel and Lodging $39,096 129 payments
  4. Food and Beverage $12,215 331 payments
  5. Honoraria $5,000 1 payment
  6. Education $49 2 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $54,637 59 payments
  2. PLEGRIDY $50,751 28 payments
  3. TECFIDERA $45,071 40 payments
  4. MAYZENT $41,112 58 payments
  5. OCREVUS $35,310 48 payments
  6. UBRELVY $34,691 38 payments
  7. ZEPOSIA $20,153 44 payments
  8. LEMTRADA $17,996 18 payments
  9. AUBAGIO $16,727 20 payments
  10. VUMERITY $15,274 9 payments
  11. Other $76,450 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $2,592 9 payments

Records

590 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record